Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Expands By 64.7%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,800 shares, a growth of 64.7% from the December 15th total of 1,700 shares. Based on an average daily volume of 17,700 shares, the short-interest ratio is currently 0.2 days.

SAB Biotherapeutics Stock Performance

SABSW stock traded down $0.05 during trading on Friday, hitting $0.10. The company had a trading volume of 2,080 shares, compared to its average volume of 12,062. The firm has a 50-day moving average price of $0.07 and a 200-day moving average price of $0.05. SAB Biotherapeutics has a 1-year low of $0.01 and a 1-year high of $0.19.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.